Menu

RIMD Research Institute for Microbial Diseases 大阪大学微生物病研究所

© Yoshioka Lab. Vaccine Creation Group, RIMD, Osaka University

研究業績Publications

最近（過去5年程度）の代表論文

  1. Kawaguchi Y, Kimura M, Karaki T, Tanaka H, Ono C, Ishida T, Matsuura Y, Hirai T, Akita H, Shimizu T, Yoshioka Y（コレスポンディングオーサー）. Modulating Immunogenicity and Reactogenicity in mRNA-Lipid Nanoparticle Vaccines through Lipid Component Optimization. ACS Nano. 2025 Aug 5;19(30):27977-28001.
  2. Hashimoto S, Hirai T, Ueda K, Kakihara M, Tokunoh N, Ono C, Matsuura Y, Takayama K, Yoshioka Y（コレスポンディングオーサー）. Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity. Mucosal Immunol. 2025 Apr 1:S1933-0219(25)00032-7.
  3. Kawai A, Shimizu T, Tanaka H, Shichinohe S, Anindita J, Hirose M, Kawahara E, Senpuku K, Shimooka M, Quynh Mai LT, Suzuki R, Nogimori T, Yamamoto T, Hirai T, Kato T, Watanabe T, Akita H, Yoshioka Y（コレスポンディングオーサー）. Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Mol Ther. 2025 Feb 5;33(2):529-547.
  4. Kawahara E, Senpuku K, Kawaguchi Y, Yamamoto S, Yasuda K, Kuroda E, Ouji-Sageshima N, Ito T, Hirai T, Shibata T, Yoshioka Y（コレスポンディングオーサー）. Recombinant RSV G protein vaccine induces enhanced respiratory disease via IL-13 and mucin overproduction. NPJ Vaccines. 2024 Oct 12;9(1):187.
  5. Kawai A, Noda M, Hirata H, Munakata L, Matsuda T, Omata D, Takemura N, Onoe S, Hirose M, Kato T, Saitoh T, Hirai T, Suzuki R, Yoshioka Y（コレスポンディングオーサー）. Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen. ACS Nano. 2024 Jul 2;18(26):16589-16609.
  6. Kawai A, Tokunoh N, Kawahara E, Tamiya S, Okamura S, Ono C, Anindita J, Tanaka H, Akita H, Yamasaki S, Kunisawa J, Okamoto T, Matsuura Y, Hirai T, Yoshioka Y（コレスポンディングオーサー）. Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses. J Clin Invest. 2023 Dec 1;133(23):e166827.
  7. Morita M, Yoneda A, Tokunoh N, Masaki T, Shirakura K, Kinoshita M, Hashimoto R, Shigesada N, Takahashi J, Tachibana M, Tanaka S, Obana M, Hino N, Ikawa M, Tsujikawa K, Ono C, Matsuura Y, Kidoya H, Takakura N, Kubota Y, Doi T, Takayama K, Yoshioka Y, Fujio Y, Okada Y. Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models. Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2213317120.
  8. Hashimoto R, Takahashi J, Shirakura K, Funatsu R, Kosugi K, Deguchi S, Yamamoto M, Tsunoda Y, Morita M, Muraoka K, Tanaka M, Kanbara T, Tanaka S, Tamiya S, Tokunoh N, Kawai A, Ikawa M, Ono C, Tachibana K, Kondoh M, Obana M, Matsuura Y, Ohsumi A, Noda T, Yamamoto T, Yoshioka Y, Torisawa YS, Date H, Fujio Y, Nagao M, Takayama K, Okada Y. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression. Sci Adv. 2022 Sep 23;8(38):eabo6783.
  9. Kitagawa S, Matsuda T, Washizaki A, Murakami A, Yamamoto T, Yoshioka Y（コレスポンディングオーサー）. Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants. NPJ Vaccines. 2022 Oct 6;7(1):115.
  10. Matsuda T, Misato K, Tamiya S, Akeda Y, Nakase I, Kuroda E, Takahama S, Nonaka M, Yamamoto T, Fukuda MN, Yoshioka Y（コレスポンディングオーサー）. Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice. iScience. 2022 Oct 10;25(11):105324.
  11. Kawai A, Yamamoto Y, Nogimori T, Takeshita K, Yamamoto T, Yoshioka Y（コレスポンディングオーサー）. The potential of neuraminidase as an antigen for nasal vaccines to increase cross-protection against influenza viruses. J Virol. 2021 Sep 27;95(20):e0118021
  12. Shibuya M, Tamiya S, Kawai A, Hirai T, Cragg MS, Yoshioka Y（コレスポンディングオーサー）. Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza. iScience. 2021 Sep 15;24(10):103131.
  13. Tamiya S, Yoshikawa E, Ogura M, Kuroda E, Suzuki K, Yoshioka Y （コレスポンディングオーサー）. Neutrophil-Mediated Lung Injury Both via TLR2-Dependent Production of IL-1α and IL-12 p40, and TLR2-Independent CARDS Toxin after Mycoplasma pneumoniae Infection in Mice. Microbiol Spectr. 2021 Dec 22;9(3):e0158821.
  14. Shibuya M, Aoshi T, Kuroda E, Yoshioka Y（コレスポンディングオーサー）. Murine cross-reactive non-neutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice. J Virol. 2020 Jun 1;94(12):e00323-20.